Publications by authors named "Jose Alberto Gomez"
Article Synopsis
- Interleukin-2 (IL-2) has been used for cancer treatment for over 30 years, but high toxicity has led to the development of mutant variants with lower toxicity and enhanced therapeutic benefits.
- The Center of Molecular Immunology has created a new variant called IL-2 no-alpha mutein, which is currently undergoing a Phase I/II clinical trial and is produced in E. coli through a process that requires refolding.
- A new purification method involving copper-catalyzed air oxidation ensures proper disulfide bond formation, resulting in a protein with improved 3D structure, higher purity, and greater biological activity compared to previous methods.
Several vaccines against COVID-19 use a recombinant SARS-CoV-2 receptor-binding domain (RBD) as antigen, making the purification of this protein a key step in their production. In this work, citrate-coated magnetic iron oxide nanoparticles were evaluated as nano adsorbents in the first step (capture) of the purification of recombinant RBD. The nanoparticles were isolated through coprecipitation and subsequently coated with sodium citrate.
View Article and Find Full Text PDFBioprocesses are of critical importance in several industries such as the food and pharmaceutical industries. Despite their importance and widespread application, bioprocess models remain rather simplistic and based on unstructured models. These simple models have limitations, making it very difficult to model complex bioprocesses.
View Article and Find Full Text PDFHumans, in contrast to other mammals, do not synthesize N-glycolyl-neuraminic acid (Neu5Gc) due to a deletion in the gene (cmah) encoding the enzyme responsible for this conversion, the cytidine monophospho-N-acetyl-neuraminic acid hydroxylase (CMP-Neu5Ac hydroxylase). The detection of considerable amounts of Neu5Gc-sialoconjugates, in particular gangliosides, in human malignancies makes these antigens attractive targets for immunotherapy, in particular with monoclonal antibodies (mAbs). We have previously described a GM3(Neu5Gc) ganglioside-specific mAb, named 14F7, with the ability to kill tumor cells in a complement-independent manner.
View Article and Find Full Text PDFObjective: To confirm the occurrence of an outbreak of viral meningitis in 1996 in the province of Tucuman, Argentina, and to study the outbreak's epidemiological characteristics.
Methods: We analyzed information from the National Epidemiological Surveillance System of the Ministry of Health (MOH) of Argentina for 1994-1998 that had been provided by the MOH's Bureau of Epidemiology. We calculated incidence rates using population estimates for the years 1994-1998 developed by the National Statistics and Census Institute, based on the 1991 census.